Notably, CXCR4 has been identified as the therapeutic target of Balixafortide, whereas AKT1 as the therapeutic target of Capivasertib and Ipatasertib, all of which have been subjected to rigorous scrutiny in phase III clinical trials for breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.